{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:35:47Z","timestamp":1790634947418,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","surgjournal.com","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.surg.2024.09.025","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T05:55:43Z","timestamp":1730267743000},"page":"108868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Effect of systemic FOLFOXIRI plus bevacizumab treatment of colorectal peritoneal metastasis on local and systemic immune cells"],"prefix":"10.1016","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-8163","authenticated-orcid":false,"given":"Catharina","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Macher-Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Birnleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Rainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Sachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Oehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bachleitner-Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2024.09.025_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","article-title":"Primary and metastatic peritoneal surface malignancies","volume":"7","author":"Cort\u00e9s-Guiral","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.surg.2024.09.025_bib2","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.surg.2024.09.025_bib3","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.surg.2024.09.025_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.surg.2024.09.025_bib5","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ejso.2021.01.018","article-title":"The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a retrospective analysis","volume":"47","author":"Repullo","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.surg.2024.09.025_bib6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Qu\u00e9net","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2024.09.025_bib7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s13046-023-02876-x","article-title":"Differential immunomodulatory effects of epirubicin\/cyclophosphamide and docetaxel in breast cancer patients","volume":"42","author":"Wimmer","year":"2023","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.surg.2024.09.025_bib8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1158\/2159-8290.CD-20-1312","article-title":"Paradigms on immunotherapy combinations with chemotherapy","volume":"11","author":"Salas-Benito","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.surg.2024.09.025_bib9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.surg.2024.09.025_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1433981","article-title":"PD-1\/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer","volume":"7","author":"Dosset","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.surg.2024.09.025_bib11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.surg.2024.09.025_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cca.2022.11.009","article-title":"Circulating caspase-cleaved cytokeratin 18 correlates with tumour burden and response to therapy in patients with colorectal cancer liver metastasis","volume":"538","author":"Singh Bhangu","year":"2023","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.surg.2024.09.025_bib13","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1537693","article-title":"Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile","volume":"8","author":"Strasser","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.surg.2024.09.025_bib14","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1245\/s10434-020-08870-3","article-title":"Cellular immunoprofile of peritoneal environment during a HIPEC procedure","volume":"27","author":"Franko","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2024.09.025_bib15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.suronc.2020.09.002","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer: the prognostic impact of baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios","volume":"35","author":"Zager","year":"2020","journal-title":"Surg Oncol"},{"key":"10.1016\/j.surg.2024.09.025_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100293","article-title":"Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI\/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO","volume":"6","author":"Rossini","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.surg.2024.09.025_bib17","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.surg.2024.09.025_bib18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s10120-016-0594-4","article-title":"Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy","volume":"20","author":"Giampieri","year":"2017","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.surg.2024.09.025_bib19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.surg.2024.09.025_bib20","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.surg.2024.09.025_bib21","doi-asserted-by":"crossref","first-page":"31411","DOI":"10.18632\/oncotarget.25830","article-title":"Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies","volume":"9","author":"Iwai","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.surg.2024.09.025_bib22","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1158\/1078-0432.CCR-21-0998","article-title":"Neoadjuvant FOLFIRINOX therapy is associated with increased effector T cells and reduced suppressor cells in patients with pancreatic cancer","volume":"27","author":"Peng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.surg.2024.09.025_bib23","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.4049\/jimmunol.176.3.1582","article-title":"CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer","volume":"176","author":"Smyth","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.surg.2024.09.025_bib24","doi-asserted-by":"crossref","first-page":"61336","DOI":"10.18632\/oncotarget.11038","article-title":"Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer","volume":"7","author":"Auer","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.surg.2024.09.025_bib25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.4287","article-title":"Towards the introduction of the 'Immunoscore' in the classification of malignant tumours","volume":"232","author":"Galon","year":"2014","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.surg.2024.09.025_bib26","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.surg.2024.09.025_bib27","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1245\/s10434-009-0585-3","article-title":"T\u00a0cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases","volume":"16","author":"Katz","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2024.09.025_bib28","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3389\/fonc.2020.00586","article-title":"FOLFOX chemotherapy ameliorates CD8 T lymphocyte exhaustion and enhances checkpoint blockade efficacy in colorectal cancer","volume":"10","author":"Guan","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.surg.2024.09.025_bib29","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1242543","article-title":"Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells","volume":"5","author":"Seebauer","year":"2016","journal-title":"OncoImmunology"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606024007943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606024007943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T21:50:58Z","timestamp":1736286658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606024007943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":29,"alternative-id":["S0039606024007943"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2024.09.025","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of systemic FOLFOXIRI plus bevacizumab treatment of colorectal peritoneal metastasis on local and systemic immune cells","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2024.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108868"}}